HLA-A*0201 Positive Cells Present

DrugDrug NameDrug Description
DB15283TebentafuspA bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma.
DrugDrug NameTargetType
DB15283TebentafuspMelanocyte protein PMELtarget
DrugDrug NamePhaseStatusCount
DB00041Aldesleukin1Completed1
DB00041Aldesleukin1Terminated1
DB00041Aldesleukin1Withdrawn1
DB01008Busulfan1Terminated1
DB00531Cyclophosphamide1Completed1
DB00099Filgrastim1Terminated1
DB00099Filgrastim1Withdrawn1
DB01073Fludarabine1Terminated1
DB17288LV3051Completed1
DB00480Lenalidomide1Withdrawn1
DB00888Mechlorethamine1Withdrawn1
DB06809Plerixafor1Terminated1
DB06809Plerixafor1Withdrawn1
DB00041Aldesleukin1 / 2Completed1
DB00041Aldesleukin1 / 2Terminated3
DB00531Cyclophosphamide1 / 2Completed1
DB00531Cyclophosphamide1 / 2Terminated2
DB01073Fludarabine1 / 2Terminated1
DB15113Utomilumab1 / 2Completed1